Sec Form 13G Filing - ALPHA CAPITAL ANSTALT filing for NLS Pharmaceutics Ltd. (NLSP) - 2024-10-15

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. __)

 

NLS PHARMACEUTICS LTD.

 

(Name of Issuer)

 

COMMON SHARES, PAR VALUE CHF 0.02 PER SHARE

 

(Title of Class of Securities)

 

H57830103

 

(CUSIP Number)

 

October 10, 2024

 

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the

disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following page(s)

 

Page 1 of 5 Pages

 

 

 

CUSIP No. H57830103 13GPage 2 of 5 Pages

 

1. NAMES OF REPORTING PERSON
  S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
   
  Alpha Capital Anstalt
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
  (a) ☐
  (b) ☐
3.   SEC USE ONLY
   
4. CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Liechtenstein

5.

SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 246,996 Common Shares (1)

   
6. SHARED VOTING POWER – None
   
7.

SOLE DISPOSITIVE POWER –246,996 Common Shares (1)

   
8. SHARED DISPOSITIVE POWER – None
   

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON –

 
     
 

246,996 Common Shares (1)

 
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☒
     
 

The aggregate amount in Row 9 represents the maximum amount that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction. The full conversion and/or exercise of Alpha Capital Anstalt’s securities would exceed this restriction.

 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
     
  9.99% (1)  
12. TYPE OF REPORTING PERSON  
     
  CO  

 

(1)Based on 2,472,438 shares outstanding as of October 11, 2024 as reported by Issuer’s Swiss counsel.

 

 

CUSIP No. H57830103 13GPage 3 of 5 Pages

 

ITEM 1(a)NAME OF ISSUER: NLS Pharmaceuticals Ltd., a Swiss corporation

 

ITEM 1(b)ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

 

The Circle 6, 8058 Zurich, Switzerland

 

ITEM 2(a)NAME OF PERSON FILING: Alpha Capital Anstalt

 

ITEM 2(b)ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

Altenbach 8, FL-9490 Vaduz, Liechtenstein

 

ITEM 2(c)CITIZENSHIP: Liechtenstein

 

ITEM 2(d)TITLE OF CLASS OF SECURITIES: Common Shares, Par Value CHF 0.02 Per Share

 

ITEM 2(e)CUSIP NUMBER: H57830103

 

ITEM 3IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

 

ITEM 4 OWNERSHIP

 

(a) AMOUNT BENEFICIALLY OWNED: 246,996 Common Shares (1)

 

(b) PERCENT OF CLASS: 9.99% (1)

 

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

 

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

 

246,996 Common Shares (1)

 

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

 

0 Shares

 

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

246,996 Common Shares (1)

 

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

0 Shares

 

 

CUSIP No. H57830103 13GPage 4 of 5 Pages

 

ITEM 5OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

Not applicable

 

ITEM 6OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

Not applicable

 

ITEM 7IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

Not applicable

 

ITEM 8IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

 

Not applicable

 

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

 

Not applicable

 

 

CUSIP No. H57830103 13GPage 5 of 5 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  October 15, 2024
  (Date)
   
  /s/ Konrad Ackermann
  (Signature)
   
  Konrad Ackermann, Director
  (Name/Title)